Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 290

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial

Open access
Mitjà, Oriol, Corbacho-Monné, Marc, Ubals, Maria, Tebé, Cristian, Peñafiel, Judith, Tobias, Aurelio, Ballana, Ester, Alemany, Andrea, Riera-Martí, Núria, Pérez, Carla A, Suñer, Clara, Laporte, Pep, Admella, Pol, Mitjà, Jordi, Clua, Mireia, Bertran, Laia, Sarquella, Maria, Gavilán, Sergi, Ara, Jordi, Argimon, Josep M, Casabona, Jordi, Cuatrecasas, Gabriel, Cañadas, Paz, Elizalde-Torrent, Aleix, Fabregat, Robert, Farré, Magí, Forcada, Anna, Flores-Mateo, Gemma, Muntada, Esteve, Nadal, Núria, Narejos, Silvia, Nieto, Aroa, Prat, Nuria, Puig, Jordi, Quiñones, Carles, Reyes-Ureña, Juliana, Ramírez-Viaplana, Ferran, Ruiz, Lidia, Riveira-Muñoz, Eva, Sierra, Alba, Velasco, César, Vivanco-Hidalgo, Rosa Maria, Sentís, Alexis, G-Beiras, Camila, Clotet, Bonaventura, Vall-Mayans, Martí · 2021 · Clinical Infectious Diseases

Abstract

Background: No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious for outpatients with COVID-19. Methods: Multicenter open-label, randomized, controlled trial conducted in Catalonia, Spain, between 17 March and 26 May 2020. Patients recently diagnosed with <5-day of symptom onset were assigned to receive HCQ (800 mg on day 1 followed by 400 mg once daily for 6 days) or usual care. Outcomes were reduction of viral load in nasopharyngeal swabs up to 7 days after treatment start, disease progression up to 28 days, and time to complete resolution of symptoms. Adverse events were assessed up to 28 days. Results: A total of 293 patients were eligible for intention-to-treat analysis: 157 in the control arm and 136 in the intervention arm. The mean age was 41.6 years (SD, 12.6), mean viral load at baseline was 7.90 log10 copies/mL (SD, 1.82), and median time from symptom onset to randomization was 3 days. No differences were found in the mean reduction of viral load at day 3 (−1.41 vs −1.41 log10 copies/mL in the control and intervention arm, respectively) or at day 7 (−3.37 vs −3.44). Treatment did not reduce risk of hospitalization (7.1% control vs 5.9% intervention) nor shorten the time to complete resolution of symptoms (12 days, control vs 10 days, intervention). No relevant adverse events were reported. Conclusions: In patients with mild COVID-19, no benefit was observed with HCQ beyond the usual care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa1009

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 22 references

Cited by

See all 290

Metadata

Authors
Mitjà, O., Corbacho-Monné, M., Ubals, M., Tebé, C., Peñafiel, J., Tobias, A., Ballana, E., Alemany, A., Riera-Martí, N., Pérez, C. A., Suñer, C., Laporte, P., Admella, P., Mitjà, J., Clua, M., Bertran, L., Sarquella, M., Gavilán, S., Ara, J., Argimon, J. M., Casabona, J., Cuatrecasas, G., Cañadas, P., Elizalde-Torrent, A., Fabregat, R., Farré, M., Forcada, A., Flores-Mateo, G., Muntada, E., Nadal, N., Narejos, S., Nieto, A., Prat, N., Puig, J., Quiñones, C., Reyes-Ureña, J., Ramírez-Viaplana, F., Ruiz, L., Riveira-Muñoz, E., Sierra, A., Velasco, C., Vivanco-Hidalgo, R. M., Sentís, A., G-Beiras, C., Clotet, B., & Vall-Mayans, M.
Venue
Clinical Infectious Diseases
Published
2020-07-16
Volume
73
Issue
11
Pages
e4073-e4081
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3043764490
Cited by
290
References
22
FWCI
8.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. https://app.cochat.ai/papers/10.1093/cid/ciaa1009
The paper
Mitjà, O., Corbacho-Monné, M., Ubals, M., Tebé, C., Peñafiel, J., Tobias, A., Ballana, E., Alemany, A., Riera-Martí, N., Pérez, C. A., Suñer, C., Laporte, P., Admella, P., Mitjà, J., Clua, M., Bertran, L., Sarquella, M., Gavilán, S., Ara, J., . . . Vall-Mayans, M. (2021). Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.